ClinicalTrials.gg
Active, not recruitingNCT05395533Updated Jun 25, 2025

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

A Phase 1 interventional study of Recombinant CD20 monoclonal antibody-MMAE conjugte for injection in CD20-positive B-cell Non-Hodgkin Lymphoma, sponsored by Zhejiang Teruisi Pharmaceutical Inc.. Active, not recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Zhejiang Teruisi Pharmaceutical Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 8 months after the study started (first participant enrolled Sep 2020, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
147
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.

Read the detailed description

The subjects were screened and examined according to the protocol before enrollment. The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, 2.1mg/kg. The incremental process is divided into groups according to the principle of 3 + 3 dose increment. The subjects randomly receive intravenous drip of TRS005 in chronological order. Each subject first carries out a single dose study, and then carries out multiple continuous doses. The first dose is given once in D1. After 21 days of observation, it is decided whether to continue multiple continuous doses according to the situation. They are given once in C2D1, C3D1, C4D1, C5D1, C6D1, or more cycles respectively, and received treatment until progressive disease or unacceptable toxicity. During the dose escalation process, the investigators will perform dose expansion according to the clinical benefits of different dose groups.

02

Conditions studied

  • CD20-positive B-cell Non-Hodgkin Lymphoma
03

In context

Lead sponsor

Zhejiang Teruisi Pharmaceutical Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed CD20-positive B-cell non-Hodgkin lymphoma;
  2. Relapse or after receiving at least 2 standard treatment regimens;(Definition of refractory: Patients who did not reach PR in two cycles or CR in four cycles);
  3. At least 1 measurable tumor lesion, the maximum transverse diameter of the intranodal lesion should be > 1.5 cm and that of the extranodal lesion should be > 1.0 cm; CLL/SLL patients have treatment indications according to iwCLL 2018 guidelines;
  4. Previously received anti-tumor treatment (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy) at least 28 days before the first administration of this study; chemotherapy and hormono therapy should be at least 14 days before the first administration of this study; Chinese medicine anti-tumor treatment should be at least 7 days before the first administration of this study
  5. The toxicity of previous anti-tumor treatment has been restored to ≤ grade 1 as defined by v5.0 (except for alopecia; see Inclusion Criterion 6 for and renal function);
  6. The laboratory test results must meet the following requirements: (It is not allowed to give any blood components, short acting cell growth factor, albumin, etc., within 7 days before laboratory examination; long acting cell growth factor is not allowed to be given within the first 14 days):

    • Hematology: (ANC) ≥ 1.5×109/L, (PLT) ≥ 90×109/L, hemoglobin (HGB) ≥ 90 g/L;
    • Liver function: (AST) and alanine aminotransferase (ALT) ≤ 3 times the , total (TBIL) ≤ 1.5 times the upper limit of normal, (AST and/or ALT ≤ 5 times the upper limit of normal are allowed in patients with liver involvement);
    • Renal function: Serum creatinine (Cr) ≤ 2 times the upper limit of normal;
    • Coagulation function: (patients who have not received anticoagulant treatment before enrollment) (INR) ≤ 1.5 times the upper limit of normal and activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal;
    • Pulmonary function test for patients with previous lung underlying disorders: measured/predicted value of vital capacity (VC) ≥ 60%, or diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50% of predicted value;
  7. ≥ 18 years , gender is not limited;
  8. performance status 0-1;
  9. of greater than 3 months;
  10. Female and male patients of childbearing age and their spouses are willing to carry out adequate throughout the study period, and female patients of childbearing age must have negative serum pregnancy test within 7 days before the first administration;
  11. Patients voluntarily agree to participate in the study and to sign the form.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded:

  1. A clear history of drug allergy, and a history of ingredient allergy to heterogeneous proteins, biological agents or test drugs;
  2. Active or C, or (HIV) antibody positive;
  3. Those who are positive for syphilis antibodies and confirmed to be unresolved;
  4. Tumor-infiltrating diseases of the central nervous system;
  5. Accompanied by peripheral or central nervous system diseases;
  6. Investigator-assessed diabetes uncontrolled by drug therapy;
  7. Uncontrollable or symptomatic pleural/abdominal/pelvic effusion or pericardial effusion;
  8. Patients with other within the past 5 years;
  9. With active diseases (such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, etc.);
  10. Accompanied by the following serious cardiovascular diseases or central nervous system diseases:

    1. Myocardial infarction in nearly 6 months of screening period;
    2. Unstable angina pectoris in the screening period of nearly 3 months;
    3. Cardiac insufficiency (cardiac function grade ≥ class II);
    4. Severe arrhythmia (e.g., persistent ventricular tachycardia, ventricular fibrillation);
    5. Prolonged (male > 450 ms, female > 470 ms);
    6. Second or third degree heart block;
    7. Drug-poorly controlled hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 100mmHg);
    8. Cerebrovascular accident (CVA) or (TIA), etc., within 6 months before the administration.
  11. Other serious diseases, including but not limited to active peptic ulcer, active hemorrhage, venous thromboembolic event (VTE) and severe interstitial lung disease;
  12. Accompanied by other serious diseases and serious active infections (such as pneumonia, active tuberculosis, etc.);
  13. Received hematopoietic growth factor treatment within 1 week prior to first administration, including colony stimulating factor, interleukin or blood transfusion;
  14. The dosage of hormone (prednisone phase equivalent) used greater than 20mg/ day within 1 month prior to first administration for more than 14 consecutive days or treatment;
  15. Various vaccines were inoculated within 1 month prior to first administration;
  16. Major surgery (except diagnostic ) within 1 month prior to first administration;
  17. Patients who received stem cell transplantation within 2 months prior to first administration;
  18. Patients who have received allogeneic stem cell transplantation in the past;
  19. Patients with infusion reaction above grade III after previous monoclonal antibody treatment;
  20. Participate in clinical trials of other drugs or medical devices within 1 month prior to first administration;
  21. Patients previously treated with CAR-T;
  22. Investigators assessed as unsuitable to participate in this study for other reasons.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Recombinant CD20 monoclonal antibody-MMAE conjugte for injection (TRS005)

    To evaluate the safety and tolerability of TRS005 in patients with recurrent or refractory CD20-positive B-cell non-Hodgkin's lymphoma with treatment at one or more times, and to recommend the dose for phase II clinical trials (RP2D).

    Drug: Recombinant CD20 monoclonal antibody-MMAE conjugte for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicity

    DLTs were defined as specific events which occurred in the 21-day DLT evaluation period of the dose escalation part, except any events that were clearly due to underlying disease or extraneous causes. The grading and severity of events were based on the guidelines provided in the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Cycle 1(Days 1-21)

  2. MTD,Maximum Tolerated Dose

    After the dose increment is completed, the incidence of DLT in each dose group is summarized and analyzed. The highest dose group closest to 1 / 3 of the preset incidence of DLT is MTD

    Time frame: Cycle 1(Days 1-21)

  3. Number of Participants With Treatment-emergent Adverse Event (TEAE)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the national cancer institute common terminology criteria for AEs, Version 5.0 (NCI-CTCAE, v5.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).

    Time frame: Baseline up to approximately 5 years

Secondary outcomes

  1. Number of Participants With ADA/Nab

    Evaluate the changes of anti drug antibody and neutralizing antibody produced by the subjects.

    Time frame: Baseline up to approximately 5 years

  2. ORR, overall response rate

    Summarize the number and percentage of objective remission (Complete remission (CR) or Partial remission (PR))

    Time frame: Baseline up to approximately 5 years

  3. DOR, duration of response

    DOR was defined as the time from the documentation of first tumor response (CR or PR) to disease progression or death.

    Time frame: Baseline up to approximately 5 years

  4. PFS, progression-free survival

    PFS was defined as the time between start of treatment and the first documentation of progression, or death.

    Time frame: Baseline up to approximately 5 years

  5. OS, overall survival

    OS was defined as the time between the start of treatment and death from any cause.

    Time frame: Baseline up to approximately 5 years

  6. Cmax

    Peak concentration. Obtained directly from the measured data of blood drug concentration-time.

    Time frame: At the day3/day5/day8/day15 in cycle 1and 4;and at the first day of Cycle 1-5 (each cycle is 21 days)

  7. AUC0-t

    Area under the curve from zero to the lowest detectable plasma concentration. Calculated by linear trapezoidal rule: AUC(i, i+1)=(Ti+1-Ti)(Ci+Ci+1)/2, AUC 0-t is the sum of all AUC (I, I + 1).

    Time frame: At the day3/day5/day8/day15 in cycle 1and 4;and at the first day of Cycle 1-5 (each cycle is 21 days)

  8. AUC0-∞

    Area under the curve extrapolated from zero to infinity time. AUC0-∞=AUC0-t+Ct/λ z(Ct is the last measurable plasma concentration)

    Time frame: At the day3/day5/day8/day15 in cycle 1and 4;and at the first day of Cycle 1-5 (each cycle is 21 days)

  9. Tmax

    Peak time. Obtained directly from the measured data of blood drug concentration-time.

    Time frame: At the day3/day5/day8/day15 in cycle 1and 4;and at the first day of Cycle 1-5 (each cycle is 21 days)

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jul 2025, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 27, 2022
StartActual
Sep 8, 2020
Primary completionEst.
Jul 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05395533
Lead sponsor
Zhejiang Teruisi Pharmaceutical Inc.
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Sep 8, 2020
Primary completion
Jul 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 25, 2025

Study contacts

Yuankai Shi, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Antibody-drug Conjugate TRS005

Start the discussion